en
en

NEWS

合一生技股份有限公司 / 2021 / Oneness Biotech and Taiwan CDE signed the agreement of regulatory science consultation and guidance on an indicator project in COVID-19 for FB704A.

Oneness Biotech and Taiwan CDE signed the agreement of regulatory science consultation and guidance on an indicator project in COVID-19 for FB704A.

2021-06-10

Published Date:2021-06-10

Original Link:https://www.onenessbio.com/en/news_detail47_3.htm

No 1 Date of announcement 2021/06/10 Time of announcement 19:50:29
Subject Oneness Biotech and Taiwan CDE signed the agreement of regulatory science consultation and guidance on an indicator project in COVID-19 for FB704A.
    
To which item it meets		 paragraph 53 Date of events 2021/06/10
Statement
1.Date of occurrence of the event:2021/06/10
2.Company name:ONENESS BIOTECH CO., LTD.
3.Relationship to the Company (please enter ”head office” or  ”subsidiaries”):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:FB704A, a new drug developed by Oneness Biotech has been included in the ”CDE can Help: COVID-19 Project Regulatory Science Consultation Program” by Taiwan Center for Drug Evaluation (CDE). Both parties have inked an agreement of regulatory science consultation and guidance on an indicator project in COVID-19 today.
6.Countermeasures:Oneness will consult and discuss with Taiwan CDE to accelerate the development of FB704A for treating COVID-19.
7.Any other matters that need to be specified:
It takes considerable time and expenses to develop a new drug of which success can’t be guaranteed. Investors shall bear such investment risk that warrants careful assessment before making investment decisions.